BIOXYNE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006 AUD | 0.00% |
|
-25.00% | -45.45% |
| 04-18 | Bioxyne to Raise AU$1.45 Million via Share Issuance | MT |
| 02-29 | Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 2.48M 1.61M 129M | Sales 2023 | 5.3M 3.45M 276M | Capitalization | 38.03M 24.7M 1.98B |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -650K -52.02M | EV / Sales 2022 | 2.22 x |
| Net cash position 2022 | 2.17M 1.41M 113M | Net cash position 2023 | 3.29M 2.14M 171M | EV / Sales 2023 | 6.55 x |
| P/E ratio 2022 |
-30.1
x | P/E ratio 2023 |
-13.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -25.00% | ||
| Current month | -50.00% | ||
| 1 month | -45.45% | ||
| 3 months | -53.85% | ||
| 6 months | -50.00% | ||
| Current year | -45.45% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.02
1 year
0.010.03
3 years
0.010.04
5 years
0.010.04
10 years
0.010.14
| Managers | Title | Age | Since |
|---|---|---|---|
Sam Watson
CEO | Chief Executive Officer | - | 18/05/23 |
Rachel Qian
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peng Ho
CHM | Chairman | 65 | 29/10/12 |
Jason Hine
BRD | Director/Board Member | - | 18/05/23 |
Sam Watson
CEO | Chief Executive Officer | - | 18/05/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 0.006 | 0.00% | 266 100 |
| 30/04/24 | 0.006 | -25.00% | 15,475,010 |
| 29/04/24 | 0.008 | 0.00% | 80,000 |
| 26/04/24 | 0.008 | +14.29% | 313,973 |
| 24/04/24 | 0.007 | -12.50% | 241,830 |
Delayed Quote Australian S.E., May 01, 2024 at 06:31 am
More quotes
Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -45.45% | 7.97M | |
| -0.20% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.51% | 24.63B | |
| -23.50% | 18.2B | |
| +27.08% | 12.01B | |
| -3.30% | 11.76B | |
| +13.03% | 10.4B | |
| -4.08% | 9.94B |
- Stock Market
- Equities
- BXN Stock
